Patrick Boen
About Patrick Boen
Patrick Boen serves as the Vice President of Clinical Development at Lyndra Therapeutics, a position he has held since 2020. He has extensive experience in clinical research and development, having worked in various leadership roles at notable pharmaceutical companies over several decades.
Work at Lyndra Therapeutics
Patrick Boen serves as the Vice President of Clinical Development at Lyndra Therapeutics. He has held this position since 2020, contributing to the company's focus on innovative drug delivery systems. His role involves overseeing clinical development strategies and ensuring the successful execution of clinical trials.
Previous Experience in Clinical Research
Prior to his current role, Patrick Boen held several significant positions in clinical research. He was Vice President of Clinical Research at Flexion Therapeutics for 10 months in 2014 to 2015. He also served as Vice President of Clinical Development at Pacira Pharmaceuticals from 2018 to 2020. His experience includes leadership roles at Merck and Forest Laboratories, where he focused on global clinical research and neurology.
Educational Background
Patrick Boen studied at Utrecht University, where he earned his MD in Medicine from 1979 to 1988. He also completed his secondary education at Libanon, achieving VWO while studying subjects including English, Dutch, Physics, Math, Biology, Chemistry, and History from 1972 to 1978.
Career at Organon and Schering-Plough
Patrick Boen has an extensive history with Organon, a part of Schering-Plough Corporation. He worked there in various roles, including Medical Research Project Manager from 1988 to 1995, Global Medical Director from 1995 to 2002, and Sr Director of Medical Affairs from 2007 to 2009. His tenure at Organon contributed to his expertise in clinical development and medical services.
Leadership Roles in the Pharmaceutical Industry
Throughout his career, Patrick Boen has held leadership positions in multiple pharmaceutical companies. He was Sr Director of Global Clinical Research at Merck for 8 months in 2009 and later returned to Merck for another 9 months in 2009 to 2010. His experience spans various therapeutic areas and includes significant contributions to clinical development and research.